Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 7
2012 23
2013 70
2014 155
2015 269
2016 322
2017 411
2018 460
2019 501
2020 528
2021 108
Text availability
Article attribute
Article type
Publication date

Search Results

2,463 results
Results by year
Filters applied: . Clear all
Page 1
Ibrutinib-Associated Atrial Fibrillation.
Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, Mahmood SS, Barac A, Groarke JD, Hayek SS, Dani S, Venesy D, Patten R, Nohria A. Ganatra S, et al. JACC Clin Electrophysiol. 2018 Dec;4(12):1491-1500. doi: 10.1016/j.jacep.2018.06.004. Epub 2018 Aug 29. JACC Clin Electrophysiol. 2018. PMID: 30573111 Free article. Review.
We reviewed the original clinical trials that led to the approval of ibrutinib, as well as several other prospective and retrospective studies, to better appreciate the incidence of ibrutinib-associated AF. ...Ibrutinib's interaction with calcium chann …
We reviewed the original clinical trials that led to the approval of ibrutinib, as well as several other prospective and retrospectiv …
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Shatzel JJ, et al. J Thromb Haemost. 2017 May;15(5):835-847. doi: 10.1111/jth.13651. Epub 2017 Mar 27. J Thromb Haemost. 2017. PMID: 28182323 Free PMC article. Review.
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders. ...In this review, we describe the pathophysiology of ibrutinib-mediated
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent
Targeting BTK in CLL: Beyond Ibrutinib.
Bond DA, Woyach JA. Bond DA, et al. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205. doi: 10.1007/s11899-019-00512-0. Curr Hematol Malig Rep. 2019. PMID: 31028669 Review.
PURPOSE OF REVIEW: While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations include off-target toxicities and the development of resistance. ...Early-phase studies are u …
PURPOSE OF REVIEW: While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic l …
Management of adverse effects/toxicity of ibrutinib.
Paydas S. Paydas S. Crit Rev Oncol Hematol. 2019 Apr;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001. Epub 2019 Feb 10. Crit Rev Oncol Hematol. 2019. PMID: 30878129 Review.
Ibrutinib has been approved by FDA for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, marginal zone lymphoma and chronic graft-versus-host disease in allogeneic stem cell transplantation. Ibrutinib is gen
Ibrutinib has been approved by FDA for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macr
Ibrutinib.
Charalambous A, Schwarzbich MA, Witzens-Harig M. Charalambous A, et al. Recent Results Cancer Res. 2018;212:133-168. doi: 10.1007/978-3-319-91439-8_7. Recent Results Cancer Res. 2018. PMID: 30069629
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor …
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (B …
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
Deeks ED. Deeks ED. Drugs. 2017 Feb;77(2):225-236. doi: 10.1007/s40265-017-0695-3. Drugs. 2017. PMID: 28105602 Review.
Ibrutinib (Imbruvica()) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias. ...Ibrutinib has an acceptable tolerability profile, a
Ibrutinib (Imbruvica()) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kina
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Hershkovitz-Rokah O, et al. Br J Haematol. 2018 May;181(3):306-319. doi: 10.1111/bjh.15108. Epub 2018 Jan 23. Br J Haematol. 2018. PMID: 29359797 Review.
Understanding the molecular events leading to the primary and acquired resistance to ibrutinib is essential for achieving better outcomes in patients with MCL. In this review, we describe the biology of the BCR signalling pathway and summarize the landmark clinical trials …
Understanding the molecular events leading to the primary and acquired resistance to ibrutinib is essential for achieving better outc …
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
Stephens DM, Byrd JC. Stephens DM, et al. Blood. 2019 Mar 21;133(12):1298-1307. doi: 10.1182/blood-2018-11-846808. Epub 2019 Jan 14. Blood. 2019. PMID: 30642919 Free PMC article. Review.
With its widespread use in clinical practice, ibrutinib's common and uncommon adverse events reported less frequently in earlier clinical trials have been experienced more frequently in real-world practice. In particular, atrial fibrillation, bleeding, infections, a …
With its widespread use in clinical practice, ibrutinib's common and uncommon adverse events reported less frequently in earli …
Cardiovascular Toxicities Associated With Ibrutinib.
Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ. Salem JE, et al. J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056. J Am Coll Cardiol. 2019. PMID: 31558250 Free article.
BACKGROUND: Ibrutinib has revolutionized treatment for several B-cell malignancies. ...Ibrutinib-associated SVA portends poor prognosis when CNS events occur concomitantly, with 28.8% deaths (15 of 52 cases). ...
BACKGROUND: Ibrutinib has revolutionized treatment for several B-cell malignancies. ...Ibrutinib-associated SVA portends poor …
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Byrd JC, et al. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. N Engl J Med. 2014. PMID: 24881631 Free PMC article. Clinical Trial.
BACKGROUND: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor o …
BACKGROUND: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or …
2,463 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page